Curis

Curis EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Curis (CRIS) as of Nov 20, 2026 is -2.16. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 0.03 — a change of -7,817.86% (lower).

EV/EBITDA

-2.16

YoY

-7,817.86%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Curis is 2025 -2.16 . EV/EBITDA (Enterprise Value to EBITDA) of Curis was 2024 0.03 . It decreases by -7,817.86% lower compared to the previous year.

The Curis EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-0.92 USD
Jan 1, 2019
0.17 USD
Jan 1, 2020
5.83 USD
Jan 1, 2021
2.31 USD
Jan 1, 2022
1.19 USD
Jan 1, 2023
0.78 USD
Jan 1, 2024
0.03 USD
Jan 1, 2025
-2.16 USD
The Curis EV/EBITDA history
YEAREV/EBITDAYoY
-2.16-7,817.86%
0.03-96.41%
0.78-34.37%
1.19-48.46%
2.31-60.41%
5.83+3,373.30%
0.17-118.23%
-0.92-1,693.22%
0.06-62.28%
0.15-79.51%
0.75+84.03%
0.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

EV/EBITDA (Enterprise Value to EBITDA) of Curis is -2.16 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Curis changed from 0.03 to -2.16, representing a -7,817.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Curis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Curis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Curis

All Key Metrics — Curis